Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rusal's investment program over the next three years will be $1.6-2 billion

7/7/23 RUAL

VTB exited the capital of Demeter Holding

7/7/23 VTBR

Shareholders of Svetofor Group approved dividends for 2022

7/6/23 SVET

Lukoil and EuroChem to invest ₽400 billion in fertilizer and ammonia production

7/6/23 LKOH

Shareholders of Novorossiysk Commercial Sea Port approved dividends for 2022

7/6/23 NMTP

General Prosecutor's Office demanded the recovery of TGK-2 shares to the state

7/6/23 TGKB

Nornickel sold its US distributor to TMP Metals Group

7/6/23 GMKN

CarMoney raised under DPO ₽978 million, of which ₽834 million came into the company's capital

7/6/23 CARM

Rusagro closed the deal to buy 50% of NMGK

7/5/23 RAGR

Shareholders of KAMAZ approved dividends for 2022

7/5/23 KMAZ